<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01326767</url>
  </required_header>
  <id_info>
    <org_study_id>C-III-002</org_study_id>
    <secondary_id>2010-023688-16</secondary_id>
    <nct_id>NCT01326767</nct_id>
  </id_info>
  <brief_title>Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring</brief_title>
  <acronym>CEPAC-TDM</acronym>
  <official_title>An Open-Label, Randomized, Parallel Group Study of Patients Treated With Paclitaxel With Standard Dosing Versus Pharmacokinetic Guided Dose Adjustment in Patients With Advanced Non Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central European Society for Anticancer Drug Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Saladax Biomedical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cantonal Hospital of St. Gallen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assign Data Management and Biostatistics GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wake Forest University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central European Society for Anticancer Drug Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be performed on grade IIIb and grade IV Non Small Cell Lung Cancer (NSCLC)
      chemotherapy naive patients with good performance status. In course of this study, patients
      will be treated with Paclitaxel in combination with either Cisplatin or Carboplatin in a
      maximum of six therapy cycles. The goal of this study is to determine, if a pharmakokinetic
      driven dose adaptation of paclitaxel leads to a reduction of of grade 4 neutropenia, compared
      to conventional Paclitaxel dosing, without affecting progression free survival and overall
      survival.

      This study includes a biomarker analysis and an optional genetic substudy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Grad 4 Neutropenia</measure>
    <time_frame>up to 6 weeks on treatment</time_frame>
    <description>The rate of grade 4 Neutropenia during the second treatment cycle between the conventional Paclitaxel dosing arm and pharmacokinetically driven Paclitaxel dosing arm is compared. At the same time progression free survival and overall survival must not be affected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response according to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST v1.1)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall neutropenia</measure>
    <time_frame>24 month</time_frame>
    <description>Overall neutropenia ( i.e. during total chemotherapy duration) assessed from clinical hematology data and by model-based estimations of individual neutrophil curves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematological / non-hematological toxicites</measure>
    <time_frame>24 months</time_frame>
    <description>Hematological (leucocytopenia, anemia, thrombocytopenia) and non-hematological toxicities (e.g. neurological, musculosceletal and gastrointestinal adverse events)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative dose and dose intensity of paclitaxel and platinum drug</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of changes from cisplatin to carboplatin and reasons thereof</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall rate of febrile neutropenia and hospitalization due to chemotherapy-associated adverse events</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economic analysis using QoL Questionnaires</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">366</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Paclitaxel dosing according to SmPC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Individualized pharmacokinetically driven paclitaxel dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the first treatment cycle, the Paclitaxel dose is adapted depending on the age and the gender of the patient. In the treatment cycles 2-6 the Paclitaxel dose is adapted based on individual PK data and toxicities.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel dosing according to SmPC</intervention_name>
    <description>Paclitaxel i.V. Up to 6 cycles Dosing according to SmPC</description>
    <arm_group_label>Paclitaxel dosing according to SmPC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Individualized pharmacokinetically driven paclitaxel dosing</intervention_name>
    <description>Paclitaxel i.V. Up to 6 cycles Dosing based on patient age, gender, severity of neutropenia and Paclitaxel plasma concentration</description>
    <arm_group_label>Individualized pharmacokinetically driven paclitaxel dosing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capable of understanding the protocol requirements and risks, and providing written
             informed consent.

          -  Patients with histologically confirmed NSCLC (stage IIIB-IV).

          -  Patients considered for first-line palliative chemotherapy with paclitaxel in
             combination with either cisplatin or carboplatin. Patients having received prior
             adjuvant non taxane-containing adjuvant chemotherapy are eligible.

          -  At least one bidimensionally measurable lesion according to RECIST 1.1.

          -  ECOG Performance Status (ECOG-PS) status ≤ 2.

          -  Female or male patients of 18 to 75 years of age at randomization

          -  Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically
             sterile) must use acceptable contraceptive methods (intrauterine device [IUD], oral
             contraceptive or double barrier device), and must have a negative serum pregnancy test
             within 1 week prior to beginning treatment on this trial. Nursing patients are
             excluded. Sexually active men must also use acceptable contraceptive methods (condom).

          -  An absolute neutrophil count &gt;1,500 cells/ mm3 (= 1.5 G/l).

          -  Platelet count &gt; 100,000/mm3.

          -  Total bilirubin ≤ 2 x upper limit of normal.

          -  AST and ALT ≤ 2.5 x upper limit of normal, or ≤ 5 x upper limit of normal in case of
             liver metastases.

          -  Creatinine clearance (according to the Cockcroft-Gault formula) ≥30ml/min. For
             patients planned to receive Cisplatin: Creatinine clearance ≥60ml/min.

          -  Patients suffering from asymptomatic brain metastases can be enrolled in case
             corticosteroid therapy is not indicated. Prior irradiation must be completed at least
             4 weeks prior to first cycle of treatment.

        Exclusion Criteria:

          -  Serious concomitant systemic disorders (e.g., active infection, severe heart disease,
             uncontrolled hypertension or diabetes mellitus) that, in the opinion of the
             investigator, would compromise the safety of the patient or compromise the patient's
             ability to complete the study.

          -  A history of hypersensitivity reactions to drugs formulated in polyoxyethylated castor
             oil.

          -  Having received prior treatment with paclitaxel or cisplatin or carboplatin (other
             drugs/drug combinations are allowed).

          -  Concomitant treatment with any targeted drug (licensed or experimental) like
             bevacizumab or cetuximab.

          -  Any condition / concomitant disease not allowing chemotherapy with paclitaxel, the
             platinum compound (carboplatin or cisplatin) or required premedication for the
             treatment regimen.

          -  Pregnant/nursing women.

          -  Individuals known to be seropositive for human immunodeficiency virus, hepatitis C
             virus, hepatitis B surface antigen or syphilis.

          -  Treatment with cytotoxic or biologic agents or any experimental drug within the 4
             weeks prior to beginning treatment on this study.

          -  Secondary malignancy within the last five years, with the exception of adequately
             treated carcinoma-in-situ of the uterine cervix, basal-cell carcinoma of the skin and
             pTa or pTis urothelial cancer.

          -  Medical or psychological conditions that would not permit the patient to complete the
             study or sign informed consent.

          -  Preexisting neuropathy &gt; grade I NCI-CTC.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Joerger, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Central European Society for Anticancer Drug Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrich Jaehde, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Central European Society for Anticancer Drug Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank Mayer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eberhard-Karls-Universität Tübingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CESAR Study Center</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CESAR study center</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CESAR Study Center</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CESAR study center</name>
      <address>
        <city>Gerlingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CESAR study center</name>
      <address>
        <city>Großhansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CESAR Study Center</name>
      <address>
        <city>Halle an der Saale</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CESAR Study Center</name>
      <address>
        <city>Leer</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CESAR Study Center</name>
      <address>
        <city>Löwenstein</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CESAR Study Center</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CESAR Study Center</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.cesar.or.at/main.asp?VID=1&amp;kat1=11&amp;kat2=397&amp;kat3=</url>
    <description>CESAR - Homepage</description>
  </link>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2011</study_first_submitted>
  <study_first_submitted_qc>March 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2011</study_first_posted>
  <last_update_submitted>January 26, 2016</last_update_submitted>
  <last_update_submitted_qc>January 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

